StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company's stock.
Several other research firms also recently issued reports on GNCA. Stifel Nicolaus downgraded Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. HC Wainwright downgraded Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th.
Get
Genocea Biosciences alerts:
Genocea Biosciences Price Performance
GNCA stock opened at $0.01 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $640,200.60, a PE ratio of -0.02 and a beta of 2.00. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.42.
Institutional Investors Weigh In On Genocea Biosciences
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC purchased a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 59.25% of the company's stock.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Why Trading Volume is Unusually High on These 3 Stocks
- Can NetApp Resume Its Rally After Strong Earnings Guidance?
- Three Reasons Why Medtronic Stock can be a Recession Winner
- Rivian Rising to the Challenge
- 3 Deflation Enablers Stocks that Can Thrive in a Recession
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company's stock.
斯托克新聞網在週四上午發佈的一份報告中開始報道Genocea Biosciences(納斯達克：GNCA-GET評級)的股票。該經紀公司對這家生物技術公司的股票發佈了賣出評級。
Several other research firms also recently issued reports on GNCA. Stifel Nicolaus downgraded Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. HC Wainwright downgraded Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th.
其他幾家研究公司最近也發佈了關於GNCA的報告。Stifel Nicolaus在4月29日星期五的一份報告中將Genocea Biosciences的評級從買入下調至持有。在4月29日星期五的一份報告中，HC Wainwright將Genocea Biosciences的評級從買入下調至中性。
Get
Genocea Biosciences
alerts:
Genocea Biosciences Price Performance
GNCA stock opened at $0.01 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $640,200.60, a PE ratio of -0.02 and a beta of 2.00. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.42.
週四，GNCA的股票開盤報0.01美元。該公司的流動比率為1.35，速動比率為1.35，債務權益比率為0.24。該公司市值為640,200.60美元，本益比為-0.02，貝塔係數為2.00。Genocea Biosciences的12個月低點為0.01美元，12個月高位為2.20美元。該業務的50日移動均線價格為0.01美元，其200日移動均線價格為0.42美元。
Institutional Investors Weigh In On Genocea Biosciences
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC purchased a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 59.25% of the company's stock.
一家對沖基金最近購買了Genocea Biosciences股票的新股份。根據Acadian Asset Management LLC在最近提交給美國證券交易委員會的13F檔案中顯示，該公司在第四季度購買了Genocea Biosciences，Inc.(納斯達克代碼：GNCA-GET Rating)的新股票頭寸。該機構投資者購買了21,741股生物技術公司的股票，價值約25,000美元。機構投資者和對沖基金持有該公司59.25%的股票。
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物製藥公司，發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Why Trading Volume is Unusually High on These 3 Stocks
- Can NetApp Resume Its Rally After Strong Earnings Guidance?
- Three Reasons Why Medtronic Stock can be a Recession Winner
- Rivian Rising to the Challenge
- 3 Deflation Enablers Stocks that Can Thrive in a Recession
- 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
- 這三隻股票的成交量為何異常高
- 在強勁的盈利指引之後，NetApp能否恢復漲勢？
- 美敦力股票可以成為經濟衰退贏家的三個原因
- Rivian迎接挑戰
- 3通縮使能在經濟衰退中蓬勃發展的股票
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
